• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in cardiovascular disease. >Reducing residual risk: modern pharmacochemistry meets old-fashioned lifestyle and adherence improvement
【24h】

Reducing residual risk: modern pharmacochemistry meets old-fashioned lifestyle and adherence improvement

机译：减少残留风险：现代药物化学满足老式生活方式并提高依从性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Despite remarkable advances in identifying and managing coronary heart disease, the global burden of cardiovascular (CV) risk and levels of undetected, subclinical heart disease remain enormous. Substantial numbers of patients do not reach their therapeutic goals, others are unable to tolerate the treatments, half may fail to adhere to their programs, and in those who do attain their targets, major cardiovascular events may continue. Well-known risk factors, such as obesity and diabetes, have now gained the upper hand, with no evidence-based remedy capable of reversing this trend. All told, less than 1% of American adults and adolescents qualify for ideal CV health; world-wide, the growing prevalence of CV risk factors in children is imposing. A number of novel emerging drug therapies are in development, some recently approved for use in patients with familial hypercholesterolemia. Hopefully, they will contribute significantly to the current therapeutic armamentarium. However, for meaningful improvement in total and residual CV risk, an optimal mix of all available modalities will likely be necessary, including earlier and more effective prevention, aggressive medical care, revascularization and device implantation, judicious use of novel agents, and reengineering of the environment.
机译：尽管在识别和管理冠心病方面取得了显着进步，但是全球心血管（CV）风险负担和未被发现的亚临床心脏病的水平仍然巨大。大量患者未达到治疗目标，其他患者无法忍受治疗，一半患者可能无法遵守其计划，并且在达到目标的患者中，重大心血管事件可能会继续。肥胖和糖尿病等众所周知的危险因素现已占据上风，没有能够逆转这一趋势的循证医学疗法。总体而言，只有不到1％的美国成年人和青少年有资格获得理想的简历健康;在全球范围内，儿童中CV危险因素的患病率正在上升。许多新的新兴药物疗法正在开发中，一些最近被批准用于家族性高胆固醇血症患者。希望它们将对当前的治疗性武器库做出重大贡献。然而，为了有意义地改善总的和残留的CV风险，可能需要所有可用方式的最佳组合，包括更早和更有效的预防，积极的医疗护理，血运重建和装置植入，明智地使用新型药物以及重新设计药物。环境。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号